NEO neogenomics.com: Price-to-Projected Revenue Ratio
NeoGenomics, Inc. (NEO) is implementing AI and DNA sequencing for precision cancer treatment, although the PAMA law is reducing the profitability of its B2B platform. The forward P/S metric helps assess this balance, with the current metric standing at 2.70. The price action smooths out the contradictions between technological leadership and regulatory pressure, while a strategic alliance with pharma behemoths accelerates the market launch of targeted therapies.
Analytical breakdowns for NeoGenomics, Inc.
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
Total Debt to Capital NeoGenomics, Inc.|NEO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital NeoGenomics, Inc.|NEO - Company Total Debt|Debt to Book Capitalization Ratio NeoGenomics Corp|NEO - Long-Term Debt Volume|Company Current Liabilities NeoGenomics|Quick Ratio neogenomics.com
- business earnings and investment ratios data:
NEO - Net Financial Result|Expected Profit NeoGenomics, Inc.|NEO - Price to Earnings Multiple|Forward P/E Multiple NeoGenomics Laboratories|NEO - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio NeoGenomics Corp|NEO - Operating income before deduction of amortization|Earnings per share for the last twelve months NeoGenomics|NEO - Earnings per share for the last 12 months|Quarterly EPS earnings growth neogenomics.com|NEO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year NeoGenomics, Inc.
- revenue and sales details:
Analysis of all company metrics:NEO (NeoGenomics)
When assessing the asset quality of NeoGenomics, Inc. (NEO), it is essential to compare current market value with revenue generation potential. The forward P/S multiple reflects the ratio of market capitalization to projected revenue, allowing for an assessment of whether the price is overextended relative to future sales. For NeoGenomics, Inc. (NEO), the high predictability of oncology testing orders mitigates the volatility risks associated with this metric. Stable cash flows provide greater protection for investment capital during extreme metric fluctuations.
Analysis of competing companies
Forward P/S Multiple LIN (Linde)|Air Products & Chemicals, Inc. (APD) - Market Cap to Future Revenue Ratio|DD - Price-to-Projected Revenue Ratio|IP (IP Corp) - Market Cap to Projected Revenue|ppg.com (PPG) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio dow.com (DOW)|Price-to-Projected Revenue Ratio LyondellBasell|Forward Price-to-Revenue Multiple IFF Inc. (IFF)|Forward P/S Multiple RPM|Market Cap to Expected Sales Ratio Entegris Corporation|Forward P/S Multiple SUZ (Suzano S.A.)|WLK - Forward Price-to-Revenue Multiple|ALB - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Israel Chemicals ICL|NEU (Afton Chemical) - Forward Price-to-Revenue Multiple|Eastman Kodak Chemical - Forward Price to Sales|AXTA (Axalta Coating Systems) - Forward P/S Multiple|elementsolutionsinc.com (ESI) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Sociedad Química y Minera de Chile (SQM)|Celanese Corp - Market Cap to Projected Revenue|Forward P/S Multiple SXT (Sensient Corp)|CBT - Forward Price-to-Revenue Multiple|HWKN: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio avient.com AVNT|H.B. Fuller (FUL) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MEOH|WDFC (WD-40 Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Chemours Co. CC|Price-to-Projected Revenue Ratio Quaker Chemical (KWR)|PCT - Market Cap to Future Revenue Ratio|Forward P/S Multiple ASH (Ashland)|NGVT - Forward Price-to-Revenue Multiple|Innospec Corp - Forward P/S Multiple|Forward Price to Sales MTX (Minerals Technologies Corp)|DQ: Forward P/S Multiple|Market Cap to Future Revenue Ratio sylvamo.com (SLVM)|Price-to-Projected Revenue Ratio Huntsman|Forward Price-to-Revenue Multiple Albany International Corp (AIN)|Forward P/S Multiple CLMT|Market Cap to Expected Sales Ratio Rogers Materials|Price-to-Projected Revenue Ratio Stepan Company SCL|Market Cap to Expected Sales Ratio ecovyst.com (ECVT)|REX: Forward Price-to-Revenue Multiple|ASP Isotopes Inc - Price to Expected Revenue Ratio|Tronox Limited (TROX) - Price-to-Projected Revenue Ratio|Ferroglobe Group - Forward Price to Sales|Forward Price-to-Revenue Multiple WLKP|Market Cap to Future Revenue Ratio compassminerals.com CMP|Price-to-Projected Revenue Ratio Kronos Worldwide (KRO)|Mativ Holdings Inc - Market Cap to Projected Revenue|Forward P/S Multiple LXU (LSB Corp)|Braskem Corp (BAK) - Market Cap to Future Revenue Ratio|KOP - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio advansix.com|OEC: Forward P/S Multiple|Projected Price to Revenue Rayonier Advanced Materials Inc. RYAM|ADUR (Aduro Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Magnera Group MAGN|Price-to-Projected Revenue Ratio Clearwater Paper (CLW)|tredegar.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Core Molding Technologies, Inc. CMT|FutureFuel Corp (FF) - Market Cap to Future Revenue Ratio|FSI - Price-to-Projected Revenue Ratio|Alto Ingredients, Inc. (ALTO) - Forward Price-to-Revenue Multiple|FEAM: Forward P/S Multiple|TSE - Market Cap to Expected Sales Ratio|ORGN (Origin Materials Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Northern Technologies International Corporation (NTIC)|Price-to-Projected Revenue Ratio LanzaTech Global Inc (LNZA)|Market Cap to Expected Sales Ratio ymaunivers.com|New Era Helium - Forward Price-to-Revenue Multiple|Forward Price to Sales BSLK|BioNexus Gene Lab Corporation - Forward P/S Multiple|Market Cap to Expected Sales Ratio Gulf Resources Inc. GURE|cneny.com (CNEY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ALTM|DNMR (Danimer Scientific) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Glatfelter Corp. (GLT)|Forward Price-to-Revenue Multiple GRFX (Graphex Group Limited)|Market Cap to Expected Sales Ratio U.S. Silica Holdings, Inc.|Price-to-Projected Revenue Ratio Invizyne IZTC
